280Bio

Executive Summary

280Bio is a Chinese biotechnology company founded in 2020 that specializes in developing orally available small molecule inhibitors targeting RAS signaling pathways in cancer. The company's core technology focuses on pan-RAS and mutation-specific inhibitors to address oncogenic drivers and resistance mechanisms in patients with KRAS, NRAS, and HRAS mutations. Based in Shanghai, 280Bio is in the Phase 1 stage and operates as a private entity with an estimated 10-50 employees. The company aims to advance precision oncology through its small molecule pipeline, though specific financial details such as total funding and valuation remain undisclosed. As an early-stage biotech, 280Bio's progress hinges on advancing its lead candidates into and through clinical trials. The RAS pathway remains a high-value target in oncology, but the company faces significant competition from other RAS inhibitors in development. Key near-term catalysts include the release of initial clinical data from ongoing Phase 1 studies, which could provide proof-of-concept for their platform. Additionally, potential partnerships with larger pharmaceutical companies or academic institutions could de-risk development and provide validation. Given the early stage and lack of publicly available data, the company's prospects are speculative but hold promise if their inhibitors demonstrate favorable safety and efficacy profiles.

Upcoming Catalysts (preview)

• TBDPhase 1 clinical data readout for lead RAS inhibitor40% success
• TBDIND submission for a second-generation RAS inhibitor50% success
• H2 2026Preclinical data presentation at major oncology conference70% success